IDiyas

For the Inventor, By the Inventor

Paris, France

Tarik Dabdoubi

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 8.9

ph-index = 4

Forward Citations = 58(Granted Patents)


Location History:

  • La Coudray Montceaux, FR (2016)
  • Le Coudray Montceaux, FR (2014 - 2017)
  • Paris, FR (2016 - 2023)

Company Filing History:

goldMedal13 out of 1,451 
 
Sanofi
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
13 patents (USPTO):
1. 12227573 - Trispecific binding proteins, methods, and uses thereof (2025-02-18),
2. 11613576 - Trispecific binding proteins, methods, and uses thereof (2023-03-28),
3. 11530268 - Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection (2022-12-20),
4. 11365261 - Anti-CD38 antibodies and methods of use (2022-06-21),
5. 11332542 - Anti-CEACAM5 antibodies and uses thereof (2022-05-17),
6. 11186649 - Anti-CD38 antibodies and methods of use (2021-11-30),
7. 10457739 - Anti-CEACAM5 antibodies and uses thereof (2019-10-29),
8. 9809653 - Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof (2017-11-07),
9. 9617345 - Anti-CEACAM5 antibodies and uses thereof (2017-04-11),
10. 9493529 - Robo1-Fc fusion protein and use thereof for treating tumours (2016-11-15),
11. 9441040 - Antagonist antibodies and their fab fragments against GPVI and uses thereof (2016-09-13),
12. 9234039 - Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same (2016-01-12),
13. 8852593 - Antagonist antibodies and their fab fragments against GPVI and uses thereof (2014-10-07),

Title: The Innovations of Tarik Dabdoubi: A Pioneer in Trispecific Binding Proteins

Introduction

Tarik Dabdoubi, a prominent inventor based in Paris, France, has made significant contributions to the field of biotechnology, specifically in the development of advanced binding proteins. With an impressive portfolio of 13 patents, Dabdoubi has positioned himself as a key figure in innovative therapeutic solutions.

Latest Patents

Among his latest patents is the groundbreaking work on trispecific binding proteins, which are complex molecules made up of four polypeptide chains that form three antigen binding sites. These proteins are designed to bind specifically to one or more target proteins and exhibit remarkable versatility. Notably, the proteins he developed have binding sites that can attach to CD28 and CD3 polypeptides, as well as other targets such as tumor proteins and HIV target proteins. His work also includes detailed methods for producing these trispecific proteins, enhancing their application in therapeutic areas.

Career Highlights

Dabdoubi currently works at Sanofi, a global leader in healthcare, where he applies his innovative ideas and expertise to further the company's pioneering research efforts. His role enables him to collaborate with other experts in the field and drives forward the development of novel medicinal products.

Collaborations

Throughout his career, Tarik has collaborated with notable coworkers such as Béatrice Cameron and Francis Blanche. Together, they contribute to a creative and effective research environment that fosters groundbreaking developments in pharmaceutical sciences.

Conclusion

Tarik Dabdoubi's contributions to the field of trispecific binding proteins exemplify the spirit of innovation. His patents and the work at Sanofi represent a proactive approach to addressing current challenges in medicine, particularly in cancer and infectious diseases. As he continues to collaborate and innovate, the impact of his work promises to reverberate through the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…